サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1377367

冠動脈ポリマーエンドステントの世界市場-2018年～2028年の世界の産業規模、シェア、動向、機会、予測：種類別、用途別、地域別、競合

Global Coronary Artery Polymer Endostents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Application By Region and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 190 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

冠動脈ポリマーエンドステントの世界市場-2018年～2028年の世界の産業規模、シェア、動向、機会、予測：種類別、用途別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 190 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

冠動脈ポリマーエンドステントの世界市場は予測期間中に力強い成長が見込まれています。

冠動脈ポリマーエンドステントの世界市場は、冠動脈疾患（CAD）の治療において極めて重要な役割を果たすヘルスケア産業において、ダイナミックかつ急速に発展している分野です。心臓に栄養を供給する血管の狭窄を特徴とする冠動脈疾患は、依然として世界の罹患率と死亡率の主要原因となっています。ポリマーエンドステントは、この問題に対処する画期的な医療ソリューションとして登場し、従来の冠動脈バイパス手術に代わる低侵襲性を提供しています。冠動脈ポリマーエンドステントは、世界の罹患率と死亡率の主要原因である冠動脈疾患（CAD）の治療に革命を起こすために設計された革新的な医療機器です。これらのステントは生体適合性ポリマーから作られた拡張可能な極小チューブであり、狭窄または閉塞した冠動脈を開口して支持するために使用されます。CADは、心臓に血液を供給する動脈が、脂肪物質であるプラークの蓄積によって狭くなったり閉塞したりすることで発生します。この市場を牽引しているのは主にCADの罹患率の増加であり、その主な原因は食生活の乱れ、座りがちな生活、高齢化などの生活習慣にあります。生体適合性材料で構成されるポリマー製エンドステントは、狭窄した冠動脈に挿入して開存性を維持し、心筋への血流を途切れさせないようにします。経皮的冠動脈インターベンション（PCI）または血管形成術として知られるこの手技は、その有効性と外科的代替術と比較した回復時間の短縮により、大きな支持を得ています。同市場では継続的な技術進歩が見られ、その結果、薬剤溶出特性の向上、生体吸収性材料、改良されたデリバリーシステムなどを備えた次世代ポリマー製エンドステントが開発されています。これらの技術革新は、再狭窄（血管狭窄の再発）や血栓症（血栓形成）といった潜在的な合併症を軽減するとともに、より迅速な治癒と組織統合を促進することを目的としています。さらに、CADの危険因子に対する意識の高まりと、新興国におけるヘルスケアインフラの改善が、市場の世界的拡大に寄与しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 冠動脈ポリマーエンドステントの世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別（PLGA、PLLA、PDLA、脱アミノ化チラミンポリカーボネートエウカテック）
    • 用途別（急性心筋梗塞、急性血管閉塞、その他）
    • 企業別（2022）
    • 地域別
  • 市場マップ

第6章 北米の冠動脈ポリマーエンドステント市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の冠動脈ポリマーエンドステント市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の冠動脈ポリマーエンドステント市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米冠動脈ポリマーエンドステントの市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカ冠動脈ポリマーエンドステント市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 PESTLE分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Eucatech AG
  • MicroPort Scientific Corporation
  • Rontis Medical
  • Meril Life Sciences
  • Alvimedica Medical Technologies
  • InSitu Technologies
  • Elixir Medical
  • SINOMED Inc
  • Amaranth Medical Inc
  • Amg International

戦略的提言

目次
Product Code: 16731

Global Coronary Artery Polymer Endostents Market is anticipated to project robust growth in the forecast period. The Global Coronary Artery Polymer Endostents Market is a dynamic and rapidly evolving sector within the healthcare industry that plays a pivotal role in the treatment of coronary artery disease (CAD). Coronary artery disease, characterized by the narrowing of blood vessels supplying the heart, remains a leading cause of morbidity and mortality worldwide. Polymer endostents have emerged as a groundbreaking medical solution to address this issue, offering a minimally invasive alternative to traditional coronary artery bypass surgery. Coronary artery polymer endostents are innovative medical devices designed to revolutionize the treatment of coronary artery disease (CAD), a leading cause of morbidity and mortality worldwide. These stents are tiny, expandable tubes made from biocompatible polymers and are used to open and support narrowed or blocked coronary arteries. CAD occurs when the arteries supplying blood to the heart become narrowed or obstructed due to the buildup of plaque, a fatty substance. This market is primarily driven by the growing incidence of CAD, largely attributed to lifestyle factors such as poor diet, sedentary behavior, and an aging population. Polymer endostents, consisting of biocompatible materials, are inserted into narrowed coronary arteries to maintain their patency and ensure uninterrupted blood flow to the heart muscle. This procedure, known as percutaneous coronary intervention (PCI) or angioplasty, has gained significant traction due to its effectiveness and reduced recovery time compared to surgical alternatives. The market has witnessed continuous technological advancements, resulting in the development of next-generation polymer endostents with enhanced drug-eluting properties, bioabsorbable materials, and improved delivery systems. These innovations aim to mitigate potential complications such as restenosis (recurrence of vessel narrowing) and thrombosis (clot formation) while promoting faster healing and tissue integration. Moreover, increasing awareness of CAD risk factors and improvements in healthcare infrastructure in emerging economies are contributing to the market's global expansion.

Key Market Drivers

Rising Incidence of Coronary Artery Disease

The rising incidence of coronary artery disease (CAD) is a pivotal driver behind the escalating growth of the Global Coronary Artery Polymer Endostents Market. Coronary artery disease remains a prominent global health concern, characterized by the narrowing or blockage of coronary arteries, which leads to restricted blood flow to the heart. Lifestyle factors, such as sedentary lifestyles, poor dietary habits, smoking, and the prevalence of risk factors like hypertension and diabetes, have significantly contributed to the increasing occurrence of CAD worldwide. As CAD cases continue to rise, the demand for effective and minimally invasive treatment options like coronary artery polymer endostents is surging. Coronary artery polymer endostents have revolutionized the management of CAD. These innovative medical devices, made from biocompatible polymers, are designed to be inserted into narrowed or blocked coronary arteries. They function as scaffolds, keeping the arteries open, and can release medication to prevent restenosis (the recurrence of vessel narrowing) and thrombosis (clot formation). Compared to traditional coronary artery bypass surgery, polymer endostents offer a less invasive approach, leading to shorter hospital stays, quicker recovery times, and reduced post-operative complications.

Furthermore, as healthcare systems globally strive for cost-effective and efficient treatment options, coronary artery polymer endostents have gained favor for their effectiveness in managing CAD while minimizing the economic burden on patients and healthcare providers. Their minimally invasive nature also aligns with the growing trend of outpatient procedures and same-day discharge protocols. With the aging population being particularly susceptible to CAD, the demographic shift toward older individuals further underscores the significance of this market driver. As people age, the risk of CAD increases, necessitating a greater emphasis on advanced treatment options like coronary artery polymer endostents.

Technological Advancements

Technological advancements are pivotal in propelling the growth of the Global Coronary Artery Polymer Endostents Market. These innovations have revolutionized the field of interventional cardiology and have significantly improved the performance, safety, and efficacy of coronary artery polymer endostents. One of the key technological advancements driving the market is the development of drug-eluting stents (DES). These stents are coated with special medications that are slowly released into the surrounding tissue after implantation. This drug-eluting feature helps to prevent restenosis, a common complication where the treated artery narrows again after stent placement. DES have become a standard in coronary artery interventions, offering superior outcomes compared to bare-metal stents. Additionally, advancements in stent materials and designs have played a crucial role. Manufacturers have introduced biocompatible polymers and innovative alloys that are not only safe for the body but also promote faster healing and reduced inflammation at the stent site. Furthermore, cutting-edge stent designs have improved flexibility, trackability, and conformability, allowing for more precise placement and reduced risk of complications during procedures. Technological developments in stent delivery systems have also contributed significantly to the market's growth. Advanced catheter designs and navigation tools enable interventional cardiologists to access and treat complex lesions with greater precision, reducing the risk of stent malposition or damage to surrounding tissues. Moreover, the use of intravascular imaging techniques like intravascular ultrasound (IVUS) and optical coherence tomography (OCT) has become more widespread, providing real-time visualization and assessment of the stent deployment, thus enhancing the procedural success rate.

Aging Population

The rising incidence of coronary artery disease (CAD) is a pivotal driver behind the escalating growth of the Global Coronary Artery Polymer Endostents Market. Coronary artery disease remains a prominent global health concern, characterized by the narrowing or blockage of coronary arteries, which leads to restricted blood flow to the heart. Lifestyle factors, such as sedentary lifestyles, poor dietary habits, smoking, and the prevalence of risk factors like hypertension and diabetes, have significantly contributed to the increasing occurrence of CAD worldwide. As CAD cases continue to rise, the demand for effective and minimally invasive treatment options like coronary artery polymer endostents is surging. Coronary artery polymer endostents have revolutionized the management of CAD. These innovative medical devices, made from biocompatible polymers, are designed to be inserted into narrowed or blocked coronary arteries. They function as scaffolds, keeping the arteries open, and can release medication to prevent restenosis (the recurrence of vessel narrowing) and thrombosis (clot formation). Compared to traditional coronary artery bypass surgery, polymer endostents offer a less invasive approach, leading to shorter hospital stays, quicker recovery times, and reduced post-operative complications.

Furthermore, as healthcare systems globally strive for cost-effective and efficient treatment options, coronary artery polymer endostents have gained favor for their effectiveness in managing CAD while minimizing the economic burden on patients and healthcare providers. Their minimally invasive nature also aligns with the growing trend of outpatient procedures and same-day discharge protocols. With the aging population being particularly susceptible to CAD, the demographic shift toward older individuals further underscores the significance of this market driver. As people age, the risk of CAD increases, necessitating a greater emphasis on advanced treatment options like coronary artery polymer endostents.

Key Market Challenges

Regulatory Hurdles

The Global Coronary Artery Polymer Endostents Market has witnessed significant advancements in medical technology and has become a crucial component in the treatment of coronary artery disease (CAD). However, despite its potential to transform cardiac care, the market faces substantial regulatory hurdles that hinder its growth and development. One of the primary challenges facing the coronary artery polymer endostents market is the complex and often stringent regulatory landscape governing medical devices. Regulatory authorities in different regions, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and various national agencies, have distinct requirements for approval and market access. This lack of harmonization leads to prolonged approval timelines and increased costs for manufacturers. Furthermore, the regulatory pathway for coronary artery polymer endostents is intricate, involving preclinical testing, clinical trials, and rigorous documentation. The high level of scrutiny is understandable, given the critical role these devices play in patient outcomes. However, the extensive regulatory requirements can significantly delay product approvals and increase development expenses.Variations in regulatory standards and expectations across different countries and regions pose a substantial challenge to manufacturers seeking global market access. Meeting the diverse demands of multiple regulatory bodies can be both resource-intensive and time-consuming. Companies often have to tailor their development and submission strategies for specific regions, further adding to the complexity and cost of bringing coronary artery polymer endostents to market.

Cost Concerns

The Global Coronary Artery Polymer Endostents Market, while offering innovative solutions for coronary artery disease (CAD), faces significant challenges, with cost concerns standing out as a prominent obstacle. Despite the undeniable benefits of coronary artery polymer endostents, the financial burden associated with their use remains a substantial barrier to their widespread adoption. Coronary artery disease is a major global health issue, and the demand for effective treatments is growing. Polymer endostents have emerged as a minimally invasive alternative to traditional coronary artery bypass surgery, offering shorter hospital stays, quicker recovery times, and reduced post-operative complications. However, these benefits come at a price, and the cost of stent procedures can be prohibitive for many patients and healthcare systems. The expense of coronary artery polymer endostent procedures can be attributed to various factors. First and foremost is the cost of the stent itself, which includes the materials used, manufacturing processes, and proprietary technologies employed by manufacturers. Additionally, the complexity of the procedure, which requires skilled interventional cardiologists, specialized equipment, and access to cardiac catheterization labs, adds to the overall cost. Post-procedure care, including medications and follow-up appointments, further contributes to the financial burden. Patients, particularly in regions with limited healthcare resources or underinsured populations, may face significant out-of-pocket expenses for coronary artery polymer endostent procedures. The financial strain can deter individuals from seeking timely treatment, potentially exacerbating their CAD condition and leading to poorer health outcomes.

Key Market Trends

Minimally Invasive Procedures

Minimally invasive procedures are playing a pivotal role in boosting the Global Coronary Artery Polymer Endostents Market. These procedures have revolutionized the treatment of coronary artery disease (CAD), offering patients and healthcare providers a less invasive and more efficient approach to cardiac care. Coronary artery polymer endostents, commonly referred to as stents, are a central component of minimally invasive procedures for CAD. They are inserted into narrowed or blocked coronary arteries to provide mechanical support and prevent re-narrowing. What sets minimally invasive procedures apart is the way these stents are deployed, typically through small incisions or catheter-based approaches rather than open-heart surgery.

One of the primary advantages of minimally invasive procedures is their reduced trauma to the patient's body. Compared to traditional open-heart surgery, which involves large incisions and significant tissue disruption, minimally invasive techniques result in less pain, less blood loss, and quicker recovery times. Patients experience shorter hospital stays and can return to their normal activities sooner, improving their overall quality of life. Moreover, the minimally invasive approach allows for faster procedural times and lower rates of post-operative complications. Cardiologists can access the coronary arteries with precision, deploy stents, and navigate through complex vessel anatomy more efficiently, reducing the risk of adverse events during the procedure.

Personalized Medicine and Precision Therapeutics

Personalized medicine and precision therapeutics are emerging as powerful drivers of growth in the Global Coronary Artery Polymer Endostents Market. These transformative trends are reshaping the landscape of cardiovascular care by tailoring treatments to individual patients based on their unique genetic and molecular profiles. In the past, one-size-fits-all approaches were common in the treatment of coronary artery disease (CAD). However, advances in genetic research and molecular diagnostics have revealed that CAD is a complex and heterogeneous condition. Patients may have distinct genetic predispositions and molecular markers that influence their response to treatments. This realization has given rise to personalized medicine, where treatment strategies are customized to match the specific needs of each patient.

Coronary artery polymer endostents play a crucial role in this paradigm shift. By integrating the principles of personalized medicine, cardiologists can now select and deploy stents that are best suited to an individual's genetic and molecular characteristics. This approach optimizes treatment outcomes by minimizing the risk of adverse reactions and maximizing the efficacy of stent placement. Precision therapeutics further enhance this personalized approach. Cardiologists can use genetic and molecular profiling to identify patients who are more likely to benefit from specific treatment strategies, including coronary artery polymer endostents. This fine-tuned approach allows for the selection of the most appropriate stent type, drug-eluting coating, and post-procedure medication regimen based on the patient's genetic makeup.

Segmental Insights

Type Insights

Based on the type, PLLA (Poly(L-lactic acid) segment emerged as the dominant player in the global market for Global Coronary Artery Polymer Endostents in 2022. PLLA has gained widespread acceptance due to its exceptional biocompatibility, biodegradability, and mechanical properties, making it an ideal material for use in coronary artery stents.

Application Insights

Based on the Application, Acute Myocardial Infarction (AMI), segment emerged as the dominant player in the global market for Global Coronary Artery Polymer Endostents in 2022. Coronary Artery Polymer Endostents are primarily used in the treatment of Acute Myocardial Infarction (AMI), which is commonly referred to as a heart attack. These stents are specifically designed to address the blockage or narrowing of coronary arteries that occurs during an AMI.

Regional Insights

North America emerged as the dominant player in the global Coronary Artery Polymer Endostents market in 2022, holding the largest market share. This is on account of several key factors such as advanced healthcare infrastructure, Strong Research and Development Ecosystem and high regulatory acceptance. North America boasts a highly advanced healthcare infrastructure, with state-of-the-art medical facilities, a well-established network of cardiac care centers, and a skilled workforce of cardiologists and interventional radiologists. This infrastructure enables the rapid adoption and utilization of innovative medical technologies such as Coronary Artery Polymer Endostents.

Key Market Players

Eucatech AG

MicroPort Scientific Corporation

Rontis Medical

Meril Life Sciences

Alvimedica Medical Technologies

InSitu Technologies

Elixir Medical

SINOMED Inc

Amaranth Medical Inc

Amg International

Report Scope:

In this report, the Global Coronary Artery Polymer Endostents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Coronary Artery Polymer Endostents Market, By Type:

  • PLGA
  • PLLA
  • PDLA
  • Deamination Tyramine Polycarbonateeucatech

Global Coronary Artery Polymer Endostents Market, By Application:

  • Acute Myocardial Infarction
  • Acute Vascular Blockage
  • Other

Global Coronary Artery Polymer Endostents Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Coronary Artery Polymer Endostents Market.

Available Customizations:

  • Global Coronary Artery Polymer Endostents market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Coronary Artery Polymer Endostents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (PLGA, PLLA, PDLA, Deamination Tyramine Polycarbonateeucatech)
    • 5.2.2. By Application (Acute Myocardial Infarction, Acute Vascular Blockage, Other)
    • 5.2.3. By Company (2022)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Coronary Artery Polymer Endostents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Coronary Artery Polymer Endostents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Coronary Artery Polymer Endostents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Coronary Artery Polymer Endostents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Coronary Artery Polymer Endostents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Coronary Artery Polymer Endostents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Coronary Artery Polymer Endostents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Coronary Artery Polymer Endostents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Coronary Artery Polymer Endostents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Coronary Artery Polymer Endostents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia-Pacific Coronary Artery Polymer Endostents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Coronary Artery Polymer Endostents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Coronary Artery Polymer Endostents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Coronary Artery Polymer Endostents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Coronary Artery Polymer Endostents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Coronary Artery Polymer Endostents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. South America Coronary Artery Polymer Endostents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Coronary Artery Polymer Endostents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Coronary Artery Polymer Endostents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Coronary Artery Polymer Endostents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. Middle East and Africa Coronary Artery Polymer Endostents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Coronary Artery Polymer Endostents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Coronary Artery Polymer Endostents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Coronary Artery Polymer Endostents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Eucatech AG
    • 15.6.2. MicroPort Scientific Corporation
    • 15.6.3. Rontis Medical
    • 15.6.4. Meril Life Sciences
    • 15.6.5. Alvimedica Medical Technologies
    • 15.6.6. InSitu Technologies
    • 15.6.7. Elixir Medical
    • 15.6.8. SINOMED Inc
    • 15.6.9. Amaranth Medical Inc
    • 15.6.10. Amg International

Strategic Recommendations